<DOC>
	<DOCNO>NCT00689221</DOCNO>
	<brief_summary>CENTRIC Phase 3 clinical trial assess efficacy safety investigational integrin inhibitor , cilengitide , combination standard treatment versus standard treatment alone newly diagnose glioblastoma subject methylated O6-methylguanine-deoxyribonucleic acid methyltransferase ( MGMT ) gene promoter tumor tissue . The MGMT gene promoter section deoxyribonucleic acid ( DNA ) act control element expression MGMT . Methylation MGMT gene promoter find predictive marker benefit temozolomide ( TMZ ) treatment .</brief_summary>
	<brief_title>Cilengitide , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Methylated Gene Promoter Status</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Tumor tissue specimens glioblastoma surgery open biopsy ( formalinfixed , paraffinembedded block ; stereotactic biopsy allow ) must available MGMT status analysis central pathology review 2 . Newly diagnose histologically proven supratentorial glioblastoma ( World Health Organization [ WHO ] Grade IV ) 3 . Proven methylated MGMT gene promoter methylation status 4 . Available postoperative gadoliniumenhanced magnetic resonance imaging ( GdMRI ) perform within less ( &lt; ) 48 hour surgery ( case possible obtain GdMRI within &lt; 48 hour post surgery , GdMRI perform prior randomization ) 5 . Stable decrease dose steroid great equal ( &gt; = ) 5 day prior randomization 6 . Eastern Cooperative Oncology Group performance score ( ECOG PS ) 01 7 . Meets 1 follow recursive partition analysis ( RPA ) classification : Class III ( Age &lt; 50 year ECOG PS 0 ) . Class IV ( meet one follow criterion : ) Age &lt; 50 year ECOG PS 1 b ) Age &gt; = 50 year , underwent prior partial total tumor resection , mini mental state examination [ MMSE ] &gt; = 27 ) . Class V ( meet one follow criterion : ) Age &gt; = 50 year underwent prior partial total tumor resection , MMSE &lt; 27 b ) Age &gt; = 50 year underwent prior tumor biopsy ) 8 . Other protocol define inclusion criterion could apply 1 . Prior chemotherapy within last 5 year 2 . Prior RTX head 3 . Receiving concurrent investigational agent receive investigational agent within past 30 day prior first dose cilengitide 4 . Prior systemic antiangiogenic therapy 5 . Placement GliadelÂ® wafer surgery 6 . Inability undergo GdMRI . 7 . Planned surgery diseases 8 . History recent peptic ulcer disease ( endoscopically proven gastric ulcer , duodenal ulcer , esophageal ulcer ) within 6 month enrollment 9 . History malignancy . Subjects curatively treated cervical carcinoma situ basal cell carcinoma skin , subject free malignancy &gt; = 5 year eligible study 10 . History coagulation disorder associate bleed recurrent thrombotic event 11 . Clinically manifest myocardial insufficiency ( New York Heart Association [ NYHA ] III , IV ) history myocardial infarction past 6 month ; uncontrolled arterial hypertension 12 . Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>newly diagnose Glioblastoma ( WHO Grade IV )</keyword>
	<keyword>Cilengitide</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>